Fulgent Genetics, Inc.

Rule 10b5-1 trading arrangements

During thethree months ended March 31, 2026, none of our directors or officers, as each term is defined in Rule 16a-1(f) of the Exchange Act, adopted or terminated “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408 of Regulation S-K, except as follows:

On March 4, 2026, Hanlin Gao, our Chief Scientific Officer and Laboratory Director, terminated a Rule 10b5-1 sales plan, intended to satisfy the affirmative defense requirements of Rule 10b5-1(c) of the Exchange Act, originally adopted on November 25, 2025, for the sale of up to 100,000 shares of our common stock. The plan was originally scheduled to terminate on January 31, 2027.

Additionally and on March 9 2026, The Ming Hsieh Trust, or the Hsieh Trust, terminated a prepaid variable forward agreement, dated as of August 21, 2023, with an unaffiliated bank, or the Prepaid Agreement, which constituted a “non‑Rule 10b5‑1 trading arrangement” as defined in Item 408 of Regulation S-K. Ming Hsieh, our Chief Executive Officer, is the trustee of the Hsieh Trust and possesses the sole voting and dispositive power with respect to securities held by the Hsieh Trust. Pursuant to the Prepaid Agreement, the Hsieh Trust pledged up to 750,000 shares of our common stock, or the Pledged Shares. On March 9, 2026, the Hsieh Trust elected toterminate the arrangement. Upon the payment of $10.7 million by the Hsieh Trust to the unaffiliated bank, the Pledged Shares were no longer subject to the Prepaid Agreement.